Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Synthetic Anti-infective Drugs >  Quinolones >  Pefloxacin

Pefloxacin

Basic information Safety Supplier Related

Pefloxacin Basic information

Product Name:
Pefloxacin
Synonyms:
  • 1-Ethyl-4-oxo-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
  • 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid
  • 1-Ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
  • N-Methylnorfloxacin
  • SULPHONATE DIHYDRATE
  • RB-1589
  • PEFLOXACIN
  • PEFLOXACINE MESYLATE DIHYDRATE
CAS:
70458-92-3
MF:
C17H20FN3O3
MW:
333.36
EINECS:
274-611-8
Mol File:
70458-92-3.mol
More
Less

Pefloxacin Chemical Properties

Melting point:
270-272° (dec)
Boiling point:
529.1±50.0 °C(Predicted)
Density 
1.320±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
Aqueous Acid (Slightly), Methanol (Slightly), Water (Slightly)
form 
Solid
pka
0.16±0.20(Predicted)
color 
White to Off-White
CAS DataBase Reference
70458-92-3(CAS DataBase Reference)
More
Less

Safety Information

Toxicity
LD50 in mice (mg/kg): 225 i.v., 1000 orally; in rats (g/kg): 1.5 i.p., 2.5 orally (Goueffon)
More
Less

Pefloxacin Usage And Synthesis

Uses

antibacterial;DNA gyrase inhibitor

Uses

Pefloxacin Mesylate Dihydrate is an analog of norfloxacin that inhibits topoisomerase.

Definition

ChEBI: A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.

Pharmaceutical Applications

A 6-fluoro, 7-piperazinyl quinoline available for oral and intravenous administration. The in-vitro activity is very similar to that of norfloxacin . It is active against H. ducreyi, V. cholerae and Legionella spp., but Campylobacter and Acinetobacter spp. and pseudomonads are not susceptible. It has poor activity against pneumococci, chlamydiae, mycoplasmas and ureaplasmas. L. monocytogenes, Nocardia spp. and anaerobes are resistant.
A plasma concentration of c. 5 mg/L is achieved 1–1.5 h after a 400 mg oral dose. The plasma elimination half-life is 8.5–15 h. It is widely distributed, concentrations in bone, brain, blister fluid, CSF, saliva, sputum and prostate all approximating, and in some cases exceeding, the simultaneous plasma concentration. It is extensively metabolized to the desmethyl (= norfloxacin) and N-oxide derivatives. Some 60–70% of a dose, only about 10% of which is unchanged, appears in the urine; 25% of a dose appears in the feces, a small part contributed by elimination in the bile.
The half-life increases with hepatic impairment, but is virtually unaffected by renal failure. In patients on continuous ambulatory peritoneal dialysis (CAPD) given 800 mg followed by 400 mg every 12 h for 10–12 days, there was no significant accumulation of pefloxacin or its metabolite, norfloxacin, but concentrations of pefloxacin N-oxide rose continuously in plasma and dialysate; all concentrations fell rapidly when treatment was discontinued.
Adverse reactions are those common to the group . Most common are gastrointestinal tract disturbances, although some typical CNS reactions have been encountered. Skin eruptions (some photosensitive) occur and rashes appeared in about one-third of a group of patients who were given longterm therapy. Clinical uses are similar to those of ofloxacin.

Pefloxacin Preparation Products And Raw materials

Raw materials

PefloxacinSupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
Shanghai Longsheng chemical Co.,Ltd.
Tel
021-58099652-8005 13585536065
Email
bin.wu@shlschem.com
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com